Prophylactic Magnesium to Decrease the Arrhythmogenic Potential of Class III Antiarrhythmic Agents in a Rabbit Model

Pharmacotherapy - Tập 19 Số 5 - Trang 635-640 - 1999
C Michael White1,2, Jianlin Xie3,2, Moses S.S. Chow4, Jeffrey Kluger5,6
1Connecticut Veterans Administration Medical Center, West Haven, Connecticut
2University of Connecticut, School of Pharmacy, Storrs, Connecticut
3Drug Information Center, Hartford Hospital, Hartford, Connecticut
4Chinese University of Hong Kong, Shatin, Hong Kong
5Department of Cardiology, Hartford Hospital, Hartford, Connecticut
6University of Connecticut School of Medicine, Farmington, Connecticut

Tóm tắt

We assessed the prophylactic effect of intravenous magnesium sulfate on the occurrence of torsades de pointes and early after‐depolarizations, and on the QT interval (QTc) in an established rabbit model. Ten rabbits were given intravenous methoxamine to slow their heart rates. After 12 minutes five animals received a 60‐mg/kg bolus and continuous infusion of magnesium 0.6 mg/kg/minute, and five received equivolume normal saline concurrently with the class III antiarrhythmic agent clofilium 5 mg/kg over 30 minutes. Electrocardiogram lead II and the monophasic action potential were recorded continuously throughout the experiment. The magnesium group experienced significantly less torsades de pointes and early after‐depolarizations than the normal saline group (1/5 and 5/5 both parameters, respectively, p= 0.048). There were no differences between groups in QT or QTc interval at baseline or at maximum QT or QTc prolongation. Magnesium decreases the occurrence of torsades de pointes without affecting the QT or QTc interval but does decrease the occurrence of early after‐depolarizations. These findings must be validated in human studies.

Từ khóa


Tài liệu tham khảo

10.1016/S0735-1097(98)00078-3

Goodman JS, 1995, Cardiac arrhythmias: their mechanisms, diagnosis, and management, 173

10.2165/00003495-199447010-00004

Tzoni D, 1988, Treatment of torsades de pointes with magnesium sulfate, Circulation, 77, 292

Baai S, 1983, Drug therapy for torsades de pointes, J Cardiovasc Electrophysiol, 4, 206

10.1111/j.1540-8159.1990.tb02131.x

Carlsson L, 1993, Attenuation of proarrhythmia related to delayed repolarization by low dose lidocaine in the anesthetized rabbit, J Pharmacol Exp Ther, 267, 1076

Buchanan LV, 1993, Comparative assessment of ibutilide, d‐sotalol, clofilium, E‐4031, and UK‐68,798 in a rabbit model of proarrhythmia, J Cardiovasc Pharmacol, 220, 540

10.1016/0735-1097(95)00046-7

10.1111/j.1540-8159.1995.tb06990.x

Roden DM, 1996, Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates, Am J Cardiol, 78, 12

10.1161/01.CIR.93.3.407

10.1161/01.RES.69.2.519

Arena JP, 1988, Block of heart potassium channels by clofilium and its tertiary analogs: relationship between drug structure and type of channel blocked, Molec Pharmacol, 34, 60

Lee KS, 1992, Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na current in guinea pig ventricular cells, J Pharmacol Exp Ther, 262, 99

10.1161/01.CIR.91.12.3010

Roden DM, 1996, Goodman and Gilman's pharmacologic basis of therapeutics, 839

10.1016/0006-2952(89)90272-4

10.1002/clc.4960150210

10.1007/BF03029780

10.1253/jcj.57.543

10.1161/01.CIR.77.6.1395

10.1161/01.CIR.86.6.1987

10.1016/0002-8703(89)90258-5

10.1111/j.1472-8206.1993.tb00215.x

10.1097/00005344-199008000-00014

10.1007/BF00265966

Critelli G, 1990, Magnesium and cardiac arrhythmias: reappraisal of an old substance, Cardiologia, 35, 39

10.1161/01.CIR.82.4.1106

10.1111/j.1540-8167.1997.tb01014.x

10.1016/S0140-6736(96)02149-6

10.1002/j.1875-9114.1997.tb03673.x

10.1056/NEJM199308123290702

10.1016/S0002-9149(96)00453-5